Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients*

Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients*

Patients with coronary heart disease or equivalent risk received a single dose of 30, 100, 300, or 500 mg of unformulated D-4F (n = 8, each dose) or placebo (n = 8) under fasting conditions. An additional 10 patients received 500 mg (n = 8) or placebo (n = 2) with a low-fat meal. There were no signi...

Full description

Bibliographic Details
Main Authors: LeAnne T. Bloedon, Richard Dunbar, Danielle Duffy, Paula Pinell-Salles, Robert Norris, Bruce J. DeGroot, Rajesh Movva, Mohamad Navab, Alan M. Fogelman, Daniel J. Rader
Format: Article
Language:English
Published: Elsevier 2008-06-01
Series:Journal of Lipid Research
Subjects:
HDL cholesterol
inflammation
atherosclerosis
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520423788

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520423788

Similar Items